KORU Medical Systems, Inc. - Common Stock (KRMD)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- Trading 955% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -21.9%
- Revenue growing at 22% annually
KORU Medical Systems, Inc. - Common Stock (KRMD) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $196 million . Key value metrics: P/E ratio 211.0, P/B ratio 11.48, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
KORU Medical Systems, Inc. - Common Stock — Fundamental Analysis Summary
KORU Medical Systems, Inc. - Common Stock (KRMD) is currently trading 955% above its Graham Number of $0.40, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 211.0x.
On financial health, KRMD shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -21.9% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.65.
StockPik's composite Value Score for KRMD is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KRMD reports a high gross margin of 62.4% (sector average: 33.5%) and a negative operating margin of -10.7%.
KRMD shows revenue growing at 22% year-over-year, with earnings growing at 57%.